Checkpoint inhibitors seek to overcome one of the cancer’s main defenses against the immune system attack. They’ve scored some impressive successes in recent years, particularly in some patients with metastatic melanoma or Hodgkin’s lymphoma, and are showing promising results in clinical trials involving patients with other types of cancer too. Apparently, with a better treatment, some side effects are also seen in many patients.
The safety profile of the Checkpoint Inhibitor Immunotherapy is discussed in this article. Checkpoint inhibitors, immunomodulatory antibodies are used to enhance the immune system, and have substantially improved the prognosis for patients with advanced melanoma and are likely to significantly improve the treatment of advanced disease in a number of other malignancies. The primary targets for checkpoint inhibition include: Programmed Cell Death receptor (PD1):…
